Treatment News : Antiretrovials Reduce Cellular Inflammation Among Elite Controllers of HIV

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2013

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 8, 2013

Antiretrovials Reduce Cellular Inflammation Among Elite Controllers of HIV

CROI 2013Elite controllers of HIV, whose immune systems keep the virus in check over long periods of time without drug therapy, experience a reduction in markers of chronic cellular inflammation when taking antiretrovirals (ARVs), MedPage Today reports. Hiroyo Hatano, MD, of the University of California at San Francisco announced the results of her and her colleagues’ study of a small cohort of elite controllers at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta.  

The study involved 16 participants who had a median viral load of 77 and a median CD4 count of 615 after a median 10 years living with HIV. All of them took a cocktail of Isentress (raltegravir) and Truvada (emtricitabine/tenofovir) for 24 weeks. The investigators found a significant drop in plasma HIV RNA, as well as a decreasing trend of cell-associated HIV RNA and gut-associated lymphoid tissue proviral DNA. In other words, there were drops in indicators of CD4 cell activation both in the participants’ blood as well as in the gut cells. There was no change in CD4 levels.  

To read the MedPage Today story, click here.

Search: Inflammation, elite controllers, MedPage Today, Hiroyo Hatano, University of California at San Francisco, 20th annual Conference on Retroviruses and Opportunistic Infections, CROI, Isentress, raltegravir, Truvada, emtricitabine, tenofovir, plasma RNA, gut-associated lymphoid tissue, proviral DNA.

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.